Relugolix + Enzalutamide Study in High-Risk Prostate Cancer

This study examines whether combining two hormone-blocking drugs — relugolix (a hormone-reducing pill) and enzalutamide (a testosterone-blocking drug) — can improve outcomes for men with high-risk, locally advanced prostate cancer. Both drugs work to lower or block the male hormones (androgens) that fuel prostate cancer growth. **You may be eligible if...** - You are 18 or older and have been diagnosed with high-risk or locally advanced prostate cancer - Your PSA is greater than 20, or your Gleason score is 8-10, or cancer has spread to nearby lymph nodes or tissue (but not distant organs) - You are a candidate for surgery or radiation therapy - Your blood counts, liver, and kidney function are within acceptable ranges **You may NOT be eligible if...** - You have prostate cancer that has spread to distant organs (metastatic disease) - You had a heart attack, heart failure, or stroke within the past 6 months - You are unable to swallow pills - You are on other investigational drugs - You have another active cancer requiring treatment Talk to your doctor to see if this trial is right for you.